Underweight: Trim 25-35% into broken technicals at premium valuation; hard-stop residual at 200 SMA
Exceptional fundamentals (54% operating margins, 102% ROE, $11B FCF) but unfavorable risk/reward from current levels due to broken technical structure (9 sessions below 50 SMA, expanding-negative MACD at -10.75, RSI ~36.98), premium valuation (23.78x forward P/E embedding 58.7% EPS growth), materially impaired balance sheet (tangible book value collapsed 51%, goodwill doubled to ~80% of equity), and GLP-1-specific macro headwinds (Trump MFN pricing framework targeting GLP-1s, Lp(a) contagion). Trim into any relief bounce, hard-stop residual at 200 SMA, and wait for technical structure repair before re-engaging.
| Position | Action |
|---|---|
| Current levels (~$1,155-$1,170) | Trim 15-20% of LLY exposure for immediate risk reduction |
| Relief bounce toward $1,165-$1,189 (10 EMA / prior consolidation) | Trim additional 10-15% of LLY exposure contingently |
| Total trim target | 25-35% total trim (per 9/4 LLY reflection: larger sizing when breakdown confirms at premium multiples) |
| Residual position after trim | Hard stop at $1,061 close (200 SMA) |
| New capital | Do not initiate positions |
| Re-entry zone flush (~$1,020-$1,040) | Add with confirmed MACD contraction and RSI>45 |
| Re-entry zone 200 SMA zone (~$1,070-$1,090) | Add with technical confirmation and RSI>45 |
| Close <$1,000 on >4M shares | Hard invalidation - exit residual entirely |
LLY's pullback from $1,280 to ~$1,124 represents a textbook mean-reversion entry at statistically-defined oversold extremes, not a regime change, given accelerating fundamentals (48% revenue growth, 77% operating income growth), a freshly expanded Mounjaro CV label, and a defensible 1.11 PEG on a 1.1x leveraged balance sheet.
| Indicator | Value | Signal |
|---|---|---|
| close | 1,123.91 | neutral |
| close_10_ema | 1,165.63 | bearish |
| close_50_sma | 1,188.70 | bearish |
| close_200_sma | 1,060.87 | bullish |
| rsi | 36.98 | bearish |
| macd | -11.10 | bearish |
| macd_histogram | -10.75 | bearish |
| bollinger_lower_band | 1,113.67 | neutral |
| bollinger_mid | 1,196.93 | neutral |
| bollinger_upper_band | 1,280.20 | neutral |
| atr |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: ~6-8 weeks out (late October/early November)
Then: Tactical reassessment; resolve bear-case balance-sheet signals (receivables/inventory/intangibles)
LLY is a defensive name with low beta that should outperform in risk-off rotations
↩ rebuts: “Bear concern about macro risk-off rotation hurting the stock”
EV: +$5.6% to +13.9% (to $1,165-$1,200 reclaim zone) · concedes: MACD histogram at -10.75 confirms short-term bearish momentum is real; VWAP did tick down from $1,204.93 to $1,199.16, confirming some volume pressure exists; 93% no-cut probability from Polymarket is a headwind for high-multiple names generally; Lp(a) overhang created real sentiment drag and peer pressure; Polymarket 3% retatrutide odds confirms approval is unlikely in 2026; NVO's lower multiple does reflect genuine valuation discount; Goodwill up 131% YoY and $3.479B unusual-item charge are real accounting events
LLY is a $1T company whose premium valuation assumes near-perfect execution of a 50%+ growth trajectory at a time when macro setup is tightening, the balance sheet has been leveraged by $7.9B in a single quarter, pipeline catalysts are priced as 2027+ events, the GLP-1 franchise faces its first real pricing-policy test under Trump MFN, technical structure has broken on heavy volume, and the CV outcomes pipeline thesis faces mechanistic doubt.
EV: $720-$840 (25-35% below current levels at forward P/E of 18-20x on normalized $40-42 EPS) · concedes: LLY's growth is genuinely superior to NVO (~47.7% vs. ~25-30%); The 1.11 PEG is the only 'reasonable' valuation metric if consensus estimates are achieved; One stumble doesn't mean permanent impairment — LLY remains a world-class pharma franchise; Defensive sector rotation into healthcare does provide some buffer in risk-off environments
→ vs conservative: Exceptional revenue growth that the market no longer pays a premium for is a value trap, not a bullish signal — tangible book value down 51%, goodwill at 80% of equity, debt up $12.4 billion in one quarter; 1.1x net debt/EBITDA ignores impairment risk from integration stumble
→ vs neutral: 1.11 PEG ratio only works if G is sustainable and multiple holds — but Fed 93% priced for zero cuts, oil at $100, and Trump MFN headwinds will compress multiples from 23.8x to 18-20x in any risk-off scenario; 'rising tail risk' acknowledged but immediately dismissed with 'fundamentals intact' is hope, not analysis
→ vs neutral: Mounjaro cardiovascular label expansion was already priced and met with sell-the-news reaction; neuroscience M&A is a multiple-expansion story irrelevant in current tape; positive bias on what exactly when bearish inputs are acute and binary while bullish inputs are structural and slow?
→ vs conservative: Holding through potential flush to 950-1,000 takes unlimited downside for the privilege of waiting — the trader's plan books gains, defines risk with stop at 1,061, and leaves residual exposure if technical repair happens; that's disciplined opportunism, not capitulation
| 35.43 |
| neutral |
| vwma | 1,199.16 | bearish |
Support: 1113.67 · 1100 · 1060.87 | Resistance: 1165.63 · 1188.7 · 1196.93 · 1199.16 · 1280.2
LLY is in a short-term pullback phase, having declined -12.2% (-$156.43) over 14 trading sessions from its $1,280.34 high on 2026-08-19 to $1,123.91 on 2026-09-08. The 50 SMA at 1,188.70 was lost on 2026-08-26, and price remains below all short-term averages, though it holds above the 200 SMA at 1,060.87. The Bollinger Lower Band tag at 1,113.67 suggests a possible bounce setup, but MACD histogram at -10.75 continues expanding negative with VWMA at 1,199.16 confirming distribution volume. Overall positioning verdict is NEUTRAL-to-DEFENSIVE with HOLD bias for long-term investors.
Market capitalization
$1.002 trillion
Implied share price
$1,124
52-week high
$1,292.65
52-week low
$712.05
50-day average
$1,191.50
200-day average
$1,063.33
TTM revenue
$79.666 billion
TTM gross profit
$66.441 billion
Vendor EBITDA
$41.707 billion
TTM net income
$26.711 billion
TTM EPS
$29.77
Forward EPS
$47.26
TTM P/E
37.75x
Forward P/E
23.78x
PEG ratio
1.11
Price-to-book
29.58x
Price-to-sales, TTM
12.6x
Price-to-free-cash-flow
74x–91x
Free-cash-flow yield
1.1%–1.4%
Return on equity
102.3%
Return on assets
20.4%
Debt-to-equity
162.1%
Current ratio
1.355x
Dividend yield
0.6%
Beta
0.502
FY2025 revenue
$65.179 billion
FY2025 gross profit
$54.127 billion
FY2025 operating income
$29.696 billion
FY2025 EBITDA
$31.693 billion
FY2025 net income
$20.640 billion
FY2025 diluted EPS
$22.95
FY2025 operating cash flow
$16.813 billion
FY2025 free cash flow
$5.964 billion
FY2025 capital expenditure
$10.849 billion
FY2025 R&D
$13.337 billion
FY2025 SG&A
$11.094 billion
FY2025 gross margin
83.0%
FY2025 operating margin
45.6%
FY2025 net margin
31.7%
Q2 2026 revenue
$22.974 billion
Q2 2026 gross profit
$19.706 billion
Q2 2026 operating income
$12.457 billion
Q2 2026 EBITDA
$12.991 billion
Q2 2026 net income
$7.095 billion
Q2 2026 diluted EPS
$7.94
Q2 2026 operating cash flow
$10.690 billion
Q2 2026 free cash flow
$4.475 billion
Q2 2026 unusual-item charge
$3.479 billion
Q2 2026 normalized income
$9.764 billion
Q2 2026 total debt
$54.908 billion
Q2 2026 net debt
$45.958 billion
Q2 2026 current ratio
1.355x
Q2 2026 goodwill and intangibles
$26.959 billion
Q2 2026 common equity
$33.879 billion
Q2 2026 tangible book value
$6.920 billion
Q2 2026 cash and equivalents
$8.950 billion
Q2 2026 net PP&E
$29.286 billion
Q2 2026 business purchases
$8.747 billion
Q2 2026 intangible purchases
$3.282 billion
Q2 2026 capital expenditure
$6.215 billion
Q2 2026 debt issuance
$8.941 billion
Q2 2026 share repurchases
$1.601 billion
Q2 2026 dividends paid
$1.546 billion
FY2025 dividends paid
$5.384 billion
FY2025 share repurchases
$4.108 billion
FY2025 debt issuance
$13.167 billion
Statement-derived TTM FCF
$13.560 billion
Vendor-reported TTM FCF
$11.066 billion
Statement-derived TTM EBITDA
$43.305 billion
Q2 2026 effective tax rate
23.3%
Q2 2025 unusual-item charge
$0.154 billion
Revenue CAGR 2022-2025
~32%
Net income CAGR 2022-2025
~49%
Diluted EPS CAGR 2022-2025
~52%
Q2 2026 working capital
$16.931 billion
Strengths
Concerns
HOLD
Macro: Mildly supportive but with rising tail risk — Iran conflict re-escalating, pushing oil to ~$100/barrel and pressuring equity multiples. Polymarket shows 93% probability of zero Fed rate cuts in 2026 (up 3.9pp in one week), indicating a restrictive-for-longer stance that is marginally negative for high-multiple growth equities like LLY (P/E in high-30s to 40s). US recession odds remain benign at 8%. Defensive sectors like healthcare should outperform on a relative basis if the Iran/oil-driven risk-off deepens.